Speech-Language Pathologists in Abingdon, MD Accepting Medicare

6 Speech-Language Pathologists found. Showing 1 - 6

Linda Cornthwaite Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2706 Philadelphia Rd, Abingdon, MD 21009 Phone: 410-612-2033

Christina Boyle, MS, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1 Laurentum Pkwy, Abingdon, MD 21009 Phone: 410-638-3900

Mrs. Clare Thacker Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 399 Singer Rd, Abingdon, MD 21009 Phone: 443-655-3037

Ebone N Hanna-dwight, M.S. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 588 Doefield Ct, Abingdon, MD 21009 Phone: 410-916-3223

Mrs. Mary Kathleen Brooks Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3054 Clarkson Dr, Abingdon, MD 21009 Phone: 443-326-4578

Kelsey Baird, MS CCC SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 417 Abbey Cir, Abingdon, MD 21009 Phone: 443-752-6099

News Archive

Monthly premiums for low-cost health plans in Massachusetts fell by 8% in second round of bidding

Monthly premiums for the four lowest-cost health plans submitted to the Massachusetts Commonwealth Health Insurance Connector Authority decreased by an average of 8% in the second round of bidding, the Boston Globe reports.

High levels of chronic stress associated with hypertension in African Americans

African Americans reporting high levels of chronic stress tended to develop high blood pressure, or hypertension, more often than those who reported low stress levels, according to new research published in the Journal of the American Heart Association, the open access journal of the American Heart Association.

Millions of H1N1 healthcare consent forms - how to manage them?

As health officials prepare to roll out millions of H1N1 swine flu vaccines this fall, many are contemplating whether to get the shot or risk coming down with the illness. Yet for officials at the state and local level, the question isn't whether to get the shot, but what to do with the millions of pages of healthcare forms that will begin piling up once the shot becomes available later this year.

Avila's AVL-292 demonstrates disease-modifying effects in prophylactic, therapeutic models of rheumatoid arthritis

Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, today announced results of preclinical studies demonstrating that its clinical candidate, AVL-292, potently inhibits B cell receptor signaling, and demonstrates efficacy in a rodent model of rheumatoid arthritis. These new data were presented Saturday, June 26, 2010 at the Federation of Clinical Immunology Societies (FOCIS) 2010 annual meeting in Boston, MA.

Read more Medical News

› Verified 6 days ago